BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zittan E, Kabakchiev B, Milgrom R, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis. 2016;10:510-515. [PMID: 26783345 DOI: 10.1093/ecco-jcc/jjw014] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Narula N, Lauzon B, Marshall JK. Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2019;54:712-7. [DOI: 10.1080/00365521.2019.1621367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Muneer S, Ayoko GA, Islam N, Izake EL. Utilizing the thiol chemistry of biomolecules for the rapid determination of anti-TNF-α drug in blood. Talanta 2020;208:120411. [DOI: 10.1016/j.talanta.2019.120411] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
3 Papamichael K, Cheifetz AS. Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis 2016;10:507-9. [PMID: 26874348 DOI: 10.1093/ecco-jcc/jjw041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
4 Ungar B, Ben-Shatach Z, Selinger L, Malik A, Albshesh A, Ben-Horin S, Eliakim R, Kopylov U, Carter D. Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease. United European Gastroenterol J 2020;8:167-74. [PMID: 32213067 DOI: 10.1177/2050640619878974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
5 Boland K, Greener T, Kabakchiev B, Stempak J, Tessolini J, Li R, Soriano J, Croitoru K, Nguyen G, Steinhart AH, Weizman AV, Silverberg MS. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn’s Disease and Ulcerative Colitis Associated With Mucosal Healing. Inflammatory Bowel Diseases 2020;26:766-73. [DOI: 10.1093/ibd/izz199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144-64. [PMID: 30137275 DOI: 10.1093/ecco-jcc/jjy113] [Cited by in Crossref: 313] [Cited by in F6Publishing: 263] [Article Influence: 104.3] [Reference Citation Analysis]
7 Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348-65. [PMID: 29431871 DOI: 10.1111/cei.13112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
8 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
9 Van den Berghe N, Gils A, Thomas D. Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted? Clin Pharmacol Ther 2019;106:945-54. [PMID: 31420861 DOI: 10.1002/cpt.1609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
10 Campbell JP, Burton E, Wymer S, Shaw M, Vaughn BP. Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3336-43. [PMID: 29052818 DOI: 10.1007/s10620-017-4808-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-1668.e3. [PMID: 30928454 DOI: 10.1016/j.cgh.2019.03.037] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 29.0] [Reference Citation Analysis]
12 Narula N, Wong ECL, AlRamdan R, Bualbanat H, Marshall JK, Steinhart AH, Greener T, Silverberg MS. Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis. J Gastroenterol Hepatol 2021. [PMID: 34020510 DOI: 10.1111/jgh.15551] [Reference Citation Analysis]
13 Choi SY, Choi YO, Choe YH, Kang B. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients. J Korean Med Sci 2020;35:e114. [PMID: 32329259 DOI: 10.3346/jkms.2020.35.e114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 30] [Article Influence: 35.3] [Reference Citation Analysis]
15 Greener T, Boland K, Steinhart AH, Silverberg MS. The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn’s Disease. Journal of Crohn's and Colitis 2018;12:458-64. [DOI: 10.1093/ecco-jcc/jjx176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
16 Yoshihara T, Shinzaki S, Kawai S, Fujii H, Iwatani S, Yamaguchi T, Araki M, Hiyama S, Inoue T, Hayashi Y, Watabe K, Iijima H, Takehara T. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:2172-9. [PMID: 28945638 DOI: 10.1097/MIB.0000000000001260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
17 Bond A, Dodd S, Fisher G, Skouras T, Subramanian S. Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy. Scand J Gastroenterol 2017;52:204-8. [PMID: 27797269 DOI: 10.1080/00365521.2016.1245777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
18 Juncadella A, Papamichael K, Vaughn BP, Cheifetz AS. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63:3067-3073. [PMID: 30006816 DOI: 10.1007/s10620-018-5202-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
19 Kim MJ, Kim E, Kang B, Choe YH. Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:870-6. [PMID: 33908743 DOI: 10.1097/MPG.0000000000003070] [Reference Citation Analysis]
20 Egan C, Doherty GA. Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment? Expert Opinion on Biological Therapy 2019;19:907-18. [DOI: 10.1080/14712598.2019.1615050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis 2020;35:1489-500. [PMID: 32592091 DOI: 10.1007/s00384-020-03663-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Plevris N, Jenkinson PW, Arnott ID, Jones GR, Lees CW. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease. Eur J Gastroenterol Hepatol. 2020;32:32-37. [PMID: 31567638 DOI: 10.1097/meg.0000000000001561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
23 Zittan E, Gralnek IM, Berns MS. The New Proactive Approach and Precision Medicine in Crohn's Disease. Biomedicines 2020;8:E193. [PMID: 32635316 DOI: 10.3390/biomedicines8070193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther 2017;46:150-61. [PMID: 28481014 DOI: 10.1111/apt.14124] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
25 Cao WT, Huang R, Jiang KF, Qiao XH, Wang JJ, Fan YH, Xu Y. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(9): 886-907 [PMID: 33727776 DOI: 10.3748/wjg.v27.i9.886] [Reference Citation Analysis]
26 Heron V, Afif W. Update on Therapeutic Drug Monitoring in Crohn's Disease. Gastroenterol Clin North Am 2017;46:645-59. [PMID: 28838420 DOI: 10.1016/j.gtc.2017.05.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
27 Govani SM, Waljee AK. Therapeutic Drug Monitoring in IBD: Prospective Promise Unfulfilled. Am J Gastroenterol 2017;112:670-2. [PMID: 28323274 DOI: 10.1038/ajg.2017.63] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Tighe D, McNamara D. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 414-425 [PMID: 28210077 DOI: 10.3748/wjg.v23.i3.414] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
29 Zittan E, Steinhart AH, Goldstein P, Milgrom R, Gralnek IM, Silverberg MS. Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease. Clin Transl Gastroenterol 2021;12:e00401. [PMID: 34613952 DOI: 10.14309/ctg.0000000000000401] [Reference Citation Analysis]
30 Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [DOI: 10.1111/apt.15643] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
31 Laserna-mendieta EJ, Salvador-martín S, Arias-gonzález L, Ruiz-ponce M, Menchén LA, Sánchez C, López-fernández LA, Lucendo AJ. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits. Clinical Chemistry and Laboratory Medicine (CCLM) 2019;57:1906-14. [DOI: 10.1515/cclm-2019-0202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
32 Feng T, Chen B, Ungar B, Qiu Y, Zhang S, He J, Lin S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis. 2019;25:1813-1821. [PMID: 30934050 DOI: 10.1093/ibd/izz061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
33 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?Curr Opin Gastroenterol. 2019;35:302-310. [PMID: 30973355 DOI: 10.1097/MOG.0000000000000536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
34 Park SH, Al-bawardy B, Aniwan S, Kane SV, Coelho-prabhu N, Papadakis KA, Kisiel JB, Bruining DH, Faubion WA, Raffals LE, Pardi DS, Tremaine WJ, Stephens MC, Tung J, Khanna S, Willrich MAV, Loftus EV. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019;1:otz047. [DOI: 10.1093/crocol/otz047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, Siegel CA. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1443-51. [PMID: 33252119 DOI: 10.1093/ibd/izaa313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Grinman AB, de Souza MDGC, Bouskela E, Carvalho ATP, de Souza HSP. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases. Medicine (Baltimore) 2020;99:e19359. [PMID: 32150077 DOI: 10.1097/MD.0000000000019359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Echarri A, Molina G, Sagastagoia O, Fuster L, Fraga R, Cid J. Letter: double-dose intensification - a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther 2019;49:821-2. [PMID: 30811638 DOI: 10.1111/apt.15124] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Grossberg LB, Papamichael K, Feuerstein JD, Siegel CA, Ullman TA, Cheifetz AS. A Survey Study of Gastroenterologists’ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:191-7. [DOI: 10.1093/ibd/izx023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
39 Senabre Gallego JM, Rosas J, Marco-mingot M, García-gómez JA, Santos-soler G, Salas-heredia E, Pons-bas A, Barber-vallés X, Bernal-vidal JA, Cano-pérez C, García-carrasco M, Flores-pardo E; AIRE-MB Group. Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. Rheumatol Int 2019;39:841-9. [DOI: 10.1007/s00296-019-04288-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
40 Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease. World J Gastroenterol 2019; 25(14): 1764-1774 [PMID: 31011260 DOI: 10.3748/wjg.v25.i14.1764] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Papamichael K, Juncadella A, Wong D, Rakowsky S, Sattler LA, Campbell JP, Vaughn BP, Cheifetz AS. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2019;13:976-981. [PMID: 30689771 DOI: 10.1093/ecco-jcc/jjz018] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 28.0] [Reference Citation Analysis]
42 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn’s Disease. Journal of Crohn's and Colitis 2018;12:653-61. [DOI: 10.1093/ecco-jcc/jjy003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
43 Battat R, Sandborn WJ. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00383-9. [PMID: 33819666 DOI: 10.1016/j.cgh.2021.03.048] [Reference Citation Analysis]
44 Freeman K, Taylor-Phillips S, Connock M, Court R, Tsertsvadze A, Shyangdan D, Auguste P, Mistry H, Arasaradnam R, Sutcliffe P, Clarke A. Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis. BMJ Open 2017;7:e014581. [PMID: 28674134 DOI: 10.1136/bmjopen-2016-014581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
45 Ma C, Battat R, Jairath V, Vande Casteele N. Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:127-45. [PMID: 30680599 DOI: 10.1007/s11938-019-00222-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
46 Carlsen A, Omdal R, Leitao KØ, Isaksen K, Hetta AK, Karlsen LN, Aabakken L, Bolstad N, Warren D, Lundin KEA, Grimstad T. Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease. Therap Adv Gastroenterol 2018;11:1756284818759930. [PMID: 29623105 DOI: 10.1177/1756284818759930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
47 Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:580-6. [PMID: 30165638 DOI: 10.1093/ibd/izy272] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
48 Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. Dig Dis Sci 2019;64:846-54. [PMID: 30426297 DOI: 10.1007/s10620-018-5362-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
49 Bian S, Lu J, Delport F, Vermeire S, Spasic D, Lammertyn J, Gils A. Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease. Drug Test Anal 2018;10:592-6. [PMID: 28743169 DOI: 10.1002/dta.2250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
50 Rocha C, Afonso J, Lago P, Arroja B, Vieira AI, Dias CC, Magro F. Accuracy of the new rapid test for monitoring adalimumab levels. Therap Adv Gastroenterol 2019;12:1756284819828238. [PMID: 30833984 DOI: 10.1177/1756284819828238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho G, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn’s Disease Are Associated With Biologic Remission. Inflammatory Bowel Diseases 2019;25:1036-43. [DOI: 10.1093/ibd/izy320] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
52 Choi SY, Kang B. Adalimumab in Pediatric Inflammatory Bowel Disease. Front Pediatr 2022;10:852580. [DOI: 10.3389/fped.2022.852580] [Reference Citation Analysis]
53 Van Steenbergen S, Bian S, Vermeire S, Van Assche G, Gils A, Ferrante M. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study. Aliment Pharmacol Ther 2017;45:923-32. [DOI: 10.1111/apt.13964] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
54 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
55 Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14:254-266. [PMID: 31403666 DOI: 10.1093/ecco-jcc/jjz131] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 25.0] [Reference Citation Analysis]
56 Silva-Ferreira F, Afonso J, Pinto-Lopes P, Magro F. A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays. Inflamm Bowel Dis. 2016;22:2289-2301. [PMID: 27508512 DOI: 10.1097/mib.0000000000000855] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
57 Mattoo VY, Basnayake C, Connell WR, Ding N, Kamm MA, Lust M, Niewiadomski O, Thompson A, Wright EK. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. Aliment Pharmacol Ther 2021;54:249-66. [PMID: 34153124 DOI: 10.1111/apt.16479] [Reference Citation Analysis]
58 Gofin Y, Matar M, Shamir R, Assa A. Therapeutic Drug Monitoring Increases Drug Retention of Anti–Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn’s Disease. Inflammatory Bowel Diseases 2019. [DOI: 10.1093/ibd/izz257] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
59 Razvi M, Lazarev M. Optimization of biologic therapy in Crohn’s disease. Expert Opinion on Biological Therapy 2017;18:263-72. [DOI: 10.1080/14712598.2018.1410131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
60 Jasurda JS, McCabe RP, Vaughn BP. Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease. Ther Drug Monit 2021;43:645-51. [PMID: 33346627 DOI: 10.1097/FTD.0000000000000849] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-horin S. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. American Journal of Gastroenterology 2018;113:890-8. [DOI: 10.1038/s41395-018-0073-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]